Ikeda M, Ioka T, Fukutomi A, Morizane C, Kasuga A, Takahashi H, Todaka A, Okusaka T, Creasy CL, Gorman S, Felitsky DJ, Kobayashi M, Zhang F, Furuse J
Cancer Sci 2018 Jan;109(1):215-224. Epub 2017 Dec 9 doi: 10.1111/cas.13438. PMID: 29121415 Free PMC Article

Myelodysplastic syndrome progresses rapidly into erythroleukemia associated with synchronous double cancers of the stomach and the papilla of Vater.

Takahashi T, Kazama Y, Shimizu H, Yoshimoto M, Tsujisaki M, Aoki S, Imai K
Int J Hematol 2001 Jul;74(1):64-9. doi: 10.1007/BF02982551. PMID: 11530807

See all (2)

Therapy

Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.

Rizzo A, Ricci AD, Brandi G
Expert Opin Investig Drugs 2021 Apr;30(4):317-324. Epub 2020 Oct 25 doi: 10.1080/13543784.2021.1837774. PMID: 33054456

Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine.

Myelodysplastic syndrome progresses rapidly into erythroleukemia associated with synchronous double cancers of the stomach and the papilla of Vater.

Takahashi T, Kazama Y, Shimizu H, Yoshimoto M, Tsujisaki M, Aoki S, Imai K
Int J Hematol 2001 Jul;74(1):64-9. doi: 10.1007/BF02982551. PMID: 11530807

See all (3)

Prognosis

Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.

Rizzo A, Ricci AD, Brandi G
Expert Opin Investig Drugs 2021 Apr;30(4):317-324. Epub 2020 Oct 25 doi: 10.1080/13543784.2021.1837774. PMID: 33054456

Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma.

Saito Y, Muramatsu T, Kanai Y, Ojima H, Sukeda A, Hiraoka N, Arai E, Sugiyama Y, Matsuzaki J, Uchida R, Yoshikawa N, Furukawa R, Saito H
Cell Rep 2019 Apr 23;27(4):1265-1276.e4. doi: 10.1016/j.celrep.2019.03.088. PMID: 31018139

See all (2)